Diagnostic Analyte to Enrich LINE-1 and Detect LINE-1 Driven Oncologic Disease

Case ID:
UA19-033
Invention:

This invention is a biomarker model, in which the biomarker detected can be used as a companion diagnostic or for screening and diagnosis of a variety of cancers. The model includes a novel liquid biopsy process that accurately measures biomarkers from blood samples by enriching for cell-derived vesicles shed directly from affected tissues. The data will eventually guide the use of tailored cancer therapies. LINE-1 has been studied as a cancer biomarker for several years; however, it is currently not a reliable biomarker in blood samples. This technique, greatly increases the accuracy and reliability of using LINE-1 as a blood biomarker.

 

Background:

Companion diagnostics are increasingly being used in precision drug therapies where patients can have differential disease pathways. By measuring various biomarkers, clinicians can build a picture of an individual’s cancer and treatment plan. Blood is an effective source of biomarkers for a particular cancer but is easily drowned out by noise from other molecules in the sample. Here, researchers have developed a fluid biopsy method that acts by enriching for molecules shed directly from affected cancer tissues and then quantifying the biomarkers separately from the blood.   

 

Applications:

  • Assays and biomarkers for early cancer detection
  • Screening technologies for lung and liver cancers
  • Cancer treatments and prevention

Advantages:

  • More accurate 
  • Enhanced personalized medicine capabilities
  • Uses blood, no need for tissue biopsy
  • Cancer screening and prevention
  • Overcomes challenges of current LINE-1 blood testing
Patent Information:
Contact For More Information:
Katherine Kuhns
Licensing Manager, UAHS-TLA
The University of Arizona
katiekuhns@email.arizona.edu
Lead Inventor(s):
Kenneth Ramos
Emma Bowers
Patrick Silva
Brian Mckay
Keywords: